Two Studies Examine Breast Cancer Tx Delay Time, Medicaid Mastectomy Rates

Share this content:
Longer Tx Delay Time Linked to Reduced Survival in Breast CA
Longer Tx Delay Time Linked to Reduced Survival in Breast CA

(HealthDay News) -- For young women with breast cancer, a longer treatment delay time (TDT) is associated with decreased survival; and women with early-stage breast cancer with Medicaid are more likely to undergo mastectomy than those with private insurance, according to two studies published online April 24 in JAMA Surgery.

Erlyn C. Smith, M.D., from the University of California in Irvine, and colleagues examined the impact of TDT on survival using data from 8,860 women aged 15 to 39 years with breast cancer. The researchers found that TDT of more than six weeks was significantly more common for Hispanic and African-American versus non-Hispanic white women, for women with no or public insurance versus private insurance, and for women with low versus high socioeconomic status. For women treated by surgery with TDT of more than six weeks, the five-year survival was 80 percent, which was significantly lower than the 90 percent for those with TDT of less than two weeks.

Linda Adepoju, M.D., from the University of Toledo Medical Center in Ohio, and colleagues examined the effect of insurance payer status on mastectomy rates for 1,539 women with early-stage breast cancer. The researchers found that, at diagnosis, women with Medicaid had significantly larger tumors and were more likely to be treated with mastectomy for large tumors than those with private insurance. Women with private insurance were significantly more likely to undergo mastectomy for smaller tumors. Overall, women with Medicaid were significantly more likely to undergo mastectomy than those with private insurance (60 versus 39 percent).

"In summary, our study demonstrates that tumor size, cancer stage, and Medicaid insurance were predictors of mastectomy," Adepoju and colleagues write.

Abstract - Smith
Full Text (subscription or payment may be required)
Abstract - Adepoju
Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs